The current financial score of Anixa Biosciences Inc is 4.67. Its financial status is weak, and its operating efficiency is low.
The current valuation score of Anixa Biosciences Inc is 8.00. Its current P/E ratio is -8.86, which is -38.90% below the recent high of -5.41 and -78.95% above the recent low of -15.85.
The current earnings forecast score of Anixa Biosciences Inc is 8.00. The average price target is 10.00, with a high of 14.00 and a low of 7.00.
The current price momentum score of Anixa Biosciences Inc is 5.40. Currently, the stock price is trading between the resistance level at 3.59 and the support level at 2.28, making it suitable for range-bound swing trading.
The current institutional shareholding score of Anixa Biosciences Inc is 3.00. The latest institutional shareholding proportion is 17.43%, representing a quarter-over-quarter decrease of 1.63%. The largest institutional shareholder is James Simons, holding a total of 59.37K shares, representing 0.00% of shares outstanding, with 146.24% increase in holdings.
The current risk assessment score of Anixa Biosciences Inc is 3.42. The company's beta value is 0.59. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.